Background: This placebo-controlled double-blind study examined the suitability of recording corneal epithelialization after phototherapeutic keratectomy (PTK) as a model of epithelial wound healing. Methods: Eighteen patients with recurrent corneal erosion were randomized into 2 groups, and received PTK with a 7-mm ablation zone. Postoperatively, one group was treated with an ointment containing 5% dexpanthenol and the other with the ointment vehicle without dexpanthenol. The epithelial lesions were recorded by digital slit-lamp photographs with fluorescein staining at fixed intervals until epithelial closure. The size of the epithelial defect was measured, and the average time until epithelial closure was calculated. Reliability of measurements was tested by calculating Cronbach’s α from measurements at the same point in time. Results: Photographs could be taken at all scheduled examinations. The measured size of the epithelial defects showed a high reliability (Cronbach’s α = 0.994). The average time needed for epithelial closure was 57.5 h in the treatment group and 64.8 h in the placebo group (p = 0.177). Conclusions: Planimetric measurement of slit-lamp photographs of standardized epithelial defects is an adequate method for monitoring the progress of corneal epithelial wound healing. Although wounds treated with dexpanthenol showed a slightly shorter average healing time, the difference to the placebo was not significant.

1.
Wood TO: Recurrent erosion. Trans Am Ophthalmol Soc 1984;82:850–898.
2.
Vegh M: Simplified microsurgical method of therapy for recurrent corneal erosion. Ger J Ophthalmol 1992;1:135–138.
3.
Maini R, Loughnan MS: Phototherapeutic keratectomy re-treatment for recurrent corneal erosion syndrome. Br J Ophthalmol 2002;86:270–272.
4.
Watson S, Barker N: Interventions for recurrent corneal erosions. Cochrane Database Syst Rev 2007:CD001861.
5.
Das S, Seitz B: Recurrent corneal erosion syndrome. Surv Ophthalmol 2008;53:3–15.
6.
Ebner F, Heller A, Rippke F, Tausch I: Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 2002;3:427–433.
7.
Haselmann G, Pulfrich K, Haselmann H: Treatment of epithelial lesions of the cornea (in German). Ophthalmologica 1952;123:357–364.
8.
Christ T: Therapie der Erosio corneae mit einem neuen panthenolhaltigen Gel. Spektrum Augenheilkd 1994;8:224–226.
9.
Göbbels M, Gross D: Klinische Studie zur Wirksamkeit eines dexpanthenolhaltigen Tränenersatzmittels (Siccaprotect) bei der Behandlung trockener Augen. Klin Monatsbl Augenheilkd 1996;209:84–88.
10.
Egger SF, Huber-Spitzy V, Alzner E, Scholda C, Vecsei VP: Corneal wound healing after superficial foreign body injury: vitamin A and dexpanthenol versus a calf blood extract. A randomized double-blind study. Ophthalmologica 1999;213:246–249.
11.
Wachtlin J, Langenbeck K, Schrunder S, Zhang EP, Hoffmann F: Immunohistology of corneal wound healing after photorefractive keratectomy and laser in situ keratomileusis. J Refract Surg 1999;15:451–458.
12.
Cavanaugh TB, Lind DM, Cutarelli PE, Mack RJ, Durrie DS, Hassanein KM, Graham CE: Phototherapeutic keratectomy for recurrent erosion syndrome in anterior basement membrane dystrophy. Ophthalmology 1999;106:971–976.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.